Skip to content

Myofascial Release and Kinesio Taping on Autonomic Nervous System in Low Back Pain

Myofascial Release and Kinesiotaping on Disability, Pain, Automic Nervous System and Oxidative Stress Indicators in Chronic Low Back Pain: A Randomized Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02067494
Acronym
I
Enrollment
64
Registered
2014-02-20
Start date
2014-02-28
Completion date
2014-11-30
Last updated
2015-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain, Chronic Disease

Keywords

Low Back Pain, Chronic Pain, Manual Therapy, Randomized Clinical Trial, Bandages

Brief summary

The purpose of this current randomized clinical trial is to determine the effects of myofascial soft tissue release and kinesio taping on disability, pain, quality of life, autonomic nervous system and oxidative stress indicators in chronic low back pain.

Detailed description

Design: Randomized Clinical Trial. Objective: to determine the effects of myofascial soft tissue release and kinesio taping on pain, disability, quality of life, and autonomic nervous system indicators. Methods and Measures: sixty-four individuals will be randomly assigned to one of two groups. Intervention: For 10-week, the group 1 will undergo treatment comprising a myofascial soft tissue release protocol (1/week) and the group 2 will recieve a kinesio taping treatment (1/week). Main Outcome Measures: Intensity of pain, disability, quality of life, biochemical stimation intertitial fluid, body mass indicators, hormonal indicators, indicators of autonomic nevous system, and indicators of oxidative stress will be collected in both groups at baseline, 10 weeks and 15 weeks after the last intervention. Baseline demographic and clinical variables will be examined between both groups with an independent Student t-test for continuous data. Separate 2x3 model ANOVA with time (baseline, 10 weeks and 15 weeks) as the within-subjects factor, group will be to determine the effects of the treatment.

Interventions

Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.

Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain.

Sponsors

Universidad de Almeria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Score ≥ 4 on the Roland Morris Disability Questionnaire. * Low Back Pain for ≥ 3 months. * Not undergoing another physical therapy treatment.

Exclusion criteria

* Disease of the central or peripheral nervous system. * Having previously undergone manual therapy. * Contraindication to low back manual therapy. * A history of spinal surgery. * Treatment with corticosteroid in the past two weeks. * Clinical sign of radiculopathy * Presence of Stenosis

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in Roland Morris Disability Questionnaire (RMDQ)At baseline, 10 weeks and 15 weeksThis is a self-reported questionnaire consisting of 24 items reflecting limitations in different activities of daily living attributed to low back pain including walking, bending over, sitting, lying down, dressing, sleeping, self-care and daily activities

Secondary

MeasureTime frameDescription
Change form baseline in Visual Analogue ScaleAt baseline, 10 weeks and 15 weeksA 10-point Numerical Pain Scale (0: no pain, 10: maximum pain) assesses the intensity of pain.
Change from baseline in Lifestyle IndicatorsAt baseline, 10 weeks and 15 weeksEstimation of interstitial fluid biochemistry and measure the following indicators: body mass, hormonal, autonomic nervous system and oxidative stress.
Change from baseline on Neural Network AnalysisAt baseline, 10 weeks and 15 weeksAnalysis of the projection on the spine and segmental innervation projection.
Change from baseline on Quality of LifeAt baseline, 10 weeks and 15 weeksSF-36 Health questionnaire scores range from 0 to 100% and indicate the self-perceived health-related quality of life.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026